FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912578916> ?p ?o ?g. }

• W2912578916 abstract "Cancer-associated fibroblasts (CAFs), one of the principal constituents of the tumor microenvironment, have a pivotal role in tumor progression. Dysregulation of microRNAs (miRNAs) in CAFs contributes to the tumor-promoting ability of CAFs. However, the mechanism underlying the involvement of miRNAs in CAFs of gastric cancer (GC) is not fully understood. This study aimed to explore the effects of miRNA-214 in CAFs on GC migration and invasion. The primary CAFs and corresponding normal fibroblasts (NFs) were isolated. Cell counting kit-8, EdU cell proliferation staining and Transwell assays were used to determine the role of miRNA-214 in GC progression. Real-time polymerase chain reaction, Western blot analysis, and dual-luciferase reporter assay were performed to verify the target genes of miRNA-214. Immunofluorescence and Western blot analysis were applied to detect the expression of epithelial–mesenchymal transition (EMT) markers. Immunohistochemistry and in situ hybridization were implemented to analyze the fibroblast growth factor 9 (FGF9) and miRNA-214 expression in human GC tissues, respectively. Finally, to assess its prognostic relevance, Kaplan–Meier survival analysis was conducted. MiRNA-214 was significantly downregulated in CAFs of GC compared with NFs. The upregulation of miRNA-214 in CAFs inhibited GC cell migration and invasion in vitro but failed to affect proliferation. Moreover, GC cells cultured with conditioned medium from CAFs transfected with miR-214 mimic showed increased expression of E-cadherin and decreased expression of Vimentin, N-cadherin and Snail, indicating the suppression of EMT of GC cells. Furthermore, FGF9 was proved to be a direct target gene of miR-214. The expression of FGF9 was higher in CAFs than that in tumor cells not only in primary tumor but also in lymph node metastatic sites (30.0% vs 11.9%, P < 0.01 and 32.1% vs 12.3%, P < 0.01, respectively). Abnormal expression of FGF9 in CAFs of lymph node metastatic sites was significantly associated with poor prognosis in patients with GC (P < 0.05). This study showed that miR-214 inhibited the tumor-promoting effect of CAFs on GC through targeting FGF9 in CAFs and regulating the EMT process in GC cells, suggesting miRNA-214/FGF9 in CAFs as a potential target for therapeutic approaches in GC." @default.
• W2912578916 created "2019-02-21" @default.
• W2912578916 creator A5006613618 @default.
• W2912578916 creator A5016476594 @default.
• W2912578916 creator A5023395286 @default.
• W2912578916 creator A5042273602 @default.
• W2912578916 creator A5045122288 @default.
• W2912578916 creator A5050964872 @default.
• W2912578916 creator A5064785596 @default.
• W2912578916 creator A5068005439 @default.
• W2912578916 date "2019-01-15" @default.
• W2912578916 modified "2023-10-18" @default.
• W2912578916 title "Downregulation of miRNA-214 in cancer-associated fibroblasts contributes to migration and invasion of gastric cancer cells through targeting FGF9 and inducing EMT" @default.
• W2912578916 cites W1153537512 @default.
• W2912578916 cites W1179357147 @default.
• W2912578916 cites W1599958157 @default.
• W2912578916 cites W1906566368 @default.
• W2912578916 cites W1968702214 @default.
• W2912578916 cites W1984420941 @default.
• W2912578916 cites W1985621107 @default.
• W2912578916 cites W1988476050 @default.
• W2912578916 cites W1994277957 @default.
• W2912578916 cites W2003793248 @default.
• W2912578916 cites W2012124753 @default.
• W2912578916 cites W2015270653 @default.
• W2912578916 cites W2018234708 @default.
• W2912578916 cites W2027230549 @default.
• W2912578916 cites W2033278321 @default.
• W2912578916 cites W2040191060 @default.
• W2912578916 cites W2044832480 @default.
• W2912578916 cites W2056062464 @default.
• W2912578916 cites W2070544193 @default.
• W2912578916 cites W2073422102 @default.
• W2912578916 cites W2076272022 @default.
• W2912578916 cites W2078615559 @default.
• W2912578916 cites W2103560672 @default.
• W2912578916 cites W2111628123 @default.
• W2912578916 cites W2121453809 @default.
• W2912578916 cites W2123250471 @default.
• W2912578916 cites W2129266710 @default.
• W2912578916 cites W2129907865 @default.
• W2912578916 cites W2134629862 @default.
• W2912578916 cites W2153301608 @default.
• W2912578916 cites W2155185375 @default.
• W2912578916 cites W2156100130 @default.
• W2912578916 cites W2264436887 @default.
• W2912578916 cites W2272984102 @default.
• W2912578916 cites W2347175105 @default.
• W2912578916 cites W2401774705 @default.
• W2912578916 cites W2512899508 @default.
• W2912578916 cites W2526296188 @default.
• W2912578916 cites W2557222435 @default.
• W2912578916 cites W2580547060 @default.
• W2912578916 cites W2592320617 @default.
• W2912578916 cites W2594744108 @default.
• W2912578916 cites W2602106112 @default.
• W2912578916 cites W2606114225 @default.
• W2912578916 cites W2783263501 @default.
• W2912578916 cites W2795707606 @default.
• W2912578916 cites W2805949429 @default.
• W2912578916 cites W2811308971 @default.
• W2912578916 cites W2889383613 @default.
• W2912578916 cites W4252499292 @default.
• W2912578916 doi "https://doi.org/10.1186/s13046-018-0995-9" @default.
• W2912578916 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6334467" @default.
• W2912578916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30646925" @default.
• W2912578916 hasPublicationYear "2019" @default.
• W2912578916 type Work @default.
• W2912578916 sameAs 2912578916 @default.
• W2912578916 citedByCount "102" @default.
• W2912578916 countsByYear W29125789162019 @default.
• W2912578916 countsByYear W29125789162020 @default.
• W2912578916 countsByYear W29125789162021 @default.
• W2912578916 countsByYear W29125789162022 @default.
• W2912578916 countsByYear W29125789162023 @default.
• W2912578916 crossrefType "journal-article" @default.
• W2912578916 hasAuthorship W2912578916A5006613618 @default.
• W2912578916 hasAuthorship W2912578916A5016476594 @default.
• W2912578916 hasAuthorship W2912578916A5023395286 @default.
• W2912578916 hasAuthorship W2912578916A5042273602 @default.
• W2912578916 hasAuthorship W2912578916A5045122288 @default.
• W2912578916 hasAuthorship W2912578916A5050964872 @default.
• W2912578916 hasAuthorship W2912578916A5064785596 @default.
• W2912578916 hasAuthorship W2912578916A5068005439 @default.
• W2912578916 hasBestOaLocation W29125789161 @default.
• W2912578916 hasConcept C104317684 @default.
• W2912578916 hasConcept C121608353 @default.
• W2912578916 hasConcept C127561419 @default.
• W2912578916 hasConcept C137738243 @default.
• W2912578916 hasConcept C145059251 @default.
• W2912578916 hasConcept C147447768 @default.
• W2912578916 hasConcept C1491633281 @default.
• W2912578916 hasConcept C203014093 @default.
• W2912578916 hasConcept C204232928 @default.
• W2912578916 hasConcept C2779013556 @default.
• W2912578916 hasConcept C502942594 @default.
• W2912578916 hasConcept C54355233 @default.
• W2912578916 hasConcept C55493867 @default.
• W2912578916 hasConcept C555283112 @default.
• W2912578916 hasConcept C62112901 @default.

• next